Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage
Completed
National Health and Medical Research Council, Australia
N/A
2005-11-01
The purpose of the study is to determine whether lowering high blood pressure levels after
the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce
the chances of a person dying or surviving with a long term disability. The study will be
undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000
patients.
Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage
Completed
The George Institute
N/A
2005-11-01
The purpose of the study is to determine whether lowering high blood pressure levels after
the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce
the chances of a person dying or surviving with a long term disability. The study will be
undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000
patients.
The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution
Completed
The Hospital for Sick Children
Phase 3
2008-07-01
The primary objective of this study is to study the acute effects of angiotensin-converting
enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional
cavopulmonary connection (BCPC) patients.
Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet
Completed
University of Virginia
N/A
2002-11-01
The kidney plays a crucial role in maintaining salt balance by two opposing physiological
mechanisms: the renal dopaminergic system which enhances salt excretion and the
renin-angiotensin system (RAS) which causes salt retention. Salt-sensitive hypertension
occurs when this balance is altered or abnormal. We hypothesized that this balance is
influenced by salt intake: therefore dietary salt affects the natriuretic response to the
renal dopaminergic agonist Fenoldopam, and the Angiotensin Converting Enzyme inhibitor,
Enalapril.
In this trial we study normal salt balance mechanisms in salt resistant adults with normal
blood pressure.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
